Improved survival at low lung function in XXXX : cohort study from 1990 to 2007.

@entity1 @entity7971 @entity204 @entity1577
OBJECTIVES: To evaluate the survival of @entity1 with @entity1577 whose lung function has deteriorated to a forced expiratory volume in one second (FEV(1)) below 30% predicted in the recent treatment @entity7971 and to explore factors associated with any change in survival. Design Cohort study. SETTING: Adult @entity1577 unit in London. @entity1 : 276 @entity1 (147 (53%) male) whose FEV(1) was first observed to be less than 30% predicted between 1 January 1990 and 31 December 2003. MAIN OUTCOME MEASURE: Survival during follow-up to 31 December 2007 in two year sub-cohorts. RESULTS: Median survival improved from 1.2 years in the 1990-1 group to 5.3 years in the 2002-3 group, with a marked improvement in survival from 1994. The use of nebulised recombinant @entity1 DNase was significantly associated with a reduced risk of @entity204 (hazard ratio 0.59, 95% confidence interval 0.44 to 0.79). Significantly increased risks were associated with a body mass index under 19 (hazard ratio 1.52, 1.10 to 2.10), long term oxygen therapy (3.52, 2.49 to 4.99), and nebulised antibiotics (1.84, 1.05 to 3.22). CONCLUSION: A marked improvement has occurred in the survival of @entity1 with @entity1577 with an FEV(1) less than 30% predicted. Secondary analyses suggest that some of this improvement may be due to use of recombinant @entity1 DNase.
